Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesInjection and Intravenous Infusion Chemotherapy and Other Highly Complex Drug or Highly Complex Biologic Agent AdministrationCPT cpt-96417-add-on-iv-chemotherapy-infusion-different-agent
    Ask Trek AI about this page

    CPT 96417: Continued Intravenous Chemotherapy Administration

    Medicare pays $69 and commercial payers pay $165 on average nationally for this procedure.

    CPT code 96417 is an add-on chemotherapy administration code used when a provider continues intravenous infusion to administer a different chemotherapy drug following a primary infusion; service type is intravenous chemotherapy infusion (continuation/add-on) and the typical site of service is an outpatient infusion center or hospital outpatient department where multi-drug IV chemotherapy is delivered.

    For related coverage guidance, see recent payer policy updates: Bendamustine Products Coverage Criteria, T-Cell Lymphoma Agents: Beleodaq, Istodax, Lymphir, Poteligeo, and Romidepsin, Brentuximab Vedotin (Adcetris®) Coverage Criteria.

    Customize your policy alerts

    Sign up for cpt 96417 policy alerts

    Get alerted when payer policies referencing 96417 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    National Reimbursement Benchmarks

    National averages show a clear gap between Medicare and commercial BUCA rates for CPT 96417: Medicare’s mean is $69.3 versus BUCA’s mean of $165.2, indicating BUCA averages about $95.9 higher per service than Medicare. That spread highlights material payment differences between a federal payer and an aggregated commercial benchmark, with Medicare centered near its median of $68 while BUCA sits closer to its $145 median.

    Dispersion across payers varies: compute P75–P25 ranges and compare relative tightness. Blue Cross Blue Shield’s range is $95 (from $151 to $246), Aetna’s is $67 (from $66.3 to $133.2), Cigna’s is $69 (from $71 to $140), UnitedHealth Group’s is $57.5 (from $69.7 to $127.5), and BUCA’s is $82 (from $115.9 to $198.1). UnitedHealth Group is the tightest band at $57.5 and Blue Cross Blue Shield the widest at $95, with BUCA and Aetna/Cigna in between.

    Table of contents

    Progress1 / 9

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools
    National Payer Mean Reimbursement Rates

    State Reimbursement Rates

    State: Alaska1 / 51

    Rate by payer

    Clinical & Coding Specifications

    Clinical Context

    A 64-year-old female with metastatic breast cancer (C50.911) presents to the outpatient oncology infusion center for multi-agent intravenous chemotherapy. The oncology team has ordered an initial primary agent administered by infusion (reported with 96413) followed by a second, different chemotherapeutic agent delivered sequentially through the same intravenous access. Nursing prepares the patient, verifies allergy and medication reconciliation, confirms consent, and establishes peripheral IV or uses an implanted port. The oncology physician documents indication, regimen, dose, planned infusion rates, and expected duration. During the visit the nurse starts the primary infusion, monitors vitals and infusion tolerance, documents the start and stop times for each agent, and then initiates the second, different chemotherapy infusion. The second infusion is reported as the add–on code 96417 to indicate continued administration of a different chemotherapy drug via intravenous infusion following the primary dose. Typical sites of service are hospital outpatient infusion centers, freestanding oncology infusion clinics, and ambulatory surgery centers when chemotherapy is delivered. Common workflow elements include verification of regimen, pharmacy compounding, nursing infusion administration with ongoing monitoring, and documentation of separate start/stop times and distinct medication names to support reporting of 96413 for the initial agent and 96417 for the subsequent different agent.

    Related CPT Codes

    CPT CodeDescription

    Related Modifiers

    6 rows

    ModifierDescriptionWhen to Use
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    76Modifier -76, Repeat Procedure or Service by Same Physician or Other Qualified Health Care Professional, is appended when the same provider performs an identical, medically necessary procedure or…- Use modifier -76 when the same physician or other qualified health care professional performs an identical procedure or service a second (or subsequent) time on the same date of service and the…
    77Modifier 77 indicates that a previously performed procedure or service was legitimately repeated by a different physician or other qualified health care professional. The AMA’s CPT definition…- Use modifier 77 when a basic procedure or service already performed is repeated by a different physician or other qualified health care professional (for example, a second provider independently…
    78CPT modifier -78 indicates an unplanned, related return to the operating or procedure room by the same provider during the global postoperative period. It is appended when treatment for a…- Use modifier -78 when an unplanned, related complication during the original procedure’s global postoperative period requires the patient to return to a formal operating or procedure room and the…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…
    91Modifier 91 — “Repeat Clinical Diagnostic Laboratory Test” — is appended when the exact same CPT laboratory test is performed more than once for the same patient on the same day because serial,…- Use modifier 91 when the exact same CPT laboratory test is performed more than once on the same patient on the same date because serial or repeated testing is medically necessary to monitor…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    207RH0003X
    207RX0202X
    163WX0200X
    207PE0005X
    207PE0004X
    163WC1500X
    261QR0400X
    207RG0100X

    Related ICD-10-CM Codes

    23 rows

    ICD-10-CM CodeDescription
    C16.9Malignant neoplasm of stomach, unspecified
    C18.9Malignant neoplasm of colon, unspecified
    C20Malignant neoplasm of rectum
    C22.0Liver cell carcinoma
    C25.9Malignant neoplasm of pancreas, unspecified
    C34.90Malignant neoplasm of unspecified part of unspecified bronchus or lung
    C43.9Malignant melanoma of skin, unspecified
    C50.911Malignant neoplasm of unspecified site of right female breast
    C53.9Malignant neoplasm of cervix uteri, unspecified
    C56.9Malignant neoplasm of unspecified ovary

    Showing 1–10 of 23

    Related Payer Policy Updates

    Specialty: Hematology/Oncology1 / 3

    10 rows

    PolicyPayerEffective Date
    Bendamustine Products Coverage Criteriablue cross blue shield - tennessee2027-01-30
    T-Cell Lymphoma Agents: Beleodaq, Istodax, Lymphir, Poteligeo, and RomidepsinMass General Brigham Health Plan2027-01-04
    Brentuximab Vedotin (Adcetris®) Coverage Criteriablue cross blue shield - tennessee2026-12-31
    Pemetrexed Coverageblue cross blue shield - tennessee2026-12-31
    Tumor Treatment Fields - Medical PolicyHealth-New-England2026-12-01
    Extracorporeal PhotopheresisCigna2026-11-15
    Hematology - AphexdaCigna2026-11-15
    VonvendiCigna2026-11-15
    Extracorporeal PhotopheresisCigna2026-11-15
    Yartemlea (narsoplimab-wuug) Coverage for TA-TMANeighborhood Health Plan of Rhode Island2026-11-01

    Related Codes

    CPT-96401-SUBCUTANEOUS-INTRAMUSCULAR-CHEMOTHERAPY-ADMINISTRATION

    CPT 96401: Subcutaneous or Intramuscular Nonhormonal Chemotherapy

    CPT-96402-SUBCUTANEOUS-INTRAMUSCULAR-HORMONAL-ANTINEOPLASTIC-ADMINISTRATION

    CPT 96402: Subcutaneous/Intramuscular Hormonal Anti‑Neoplastic Administration

    CPT-96405-INTRALESIONAL-CHEMOTHERAPY-ONE-TO-SEVEN-LESIONS

    CPT 96405: Intralesional Chemotherapy, 1–7 Lesions

    CPT-96406-INTRALESIONAL-CHEMOTHERAPY-MORE-THAN-7-LESIONS

    CPT 96406: Intralesional Chemotherapy for >7 Lesions

    CPT-96409-INTRAVENOUS-PUSH-CHEMOTHERAPY-INITIAL-DRUG

    CPT 96409: Intravenous Push Chemotherapy, Single/Initial Drug

    CPT-96411-ADD-ON-INTRAVENOUS-PUSH-CHEMOTHERAPY-DRUG

    CPT 96411: Add-On IV Push for Additional Chemotherapy Drug

    CPT-96413-INTRAVENOUS-CHEMOTHERAPY-INFUSION-INITIAL-HOUR

    CPT 96413: Intravenous Chemotherapy Infusion, Initial Hour

    CPT-96415-ADDITIONAL-HOUR-CHEMOTHERAPY-INTRAVENOUS-INFUSION

    CPT 96415: Continued Intravenous Chemotherapy Infusion, Per Additional Hour

    CPT-96416-CHEMOTHERAPY-INITIATION-PORTABLE-IMPLANTABLE-PUMP

    CPT 96416: Initiation of Intravenous Chemotherapy via Pump

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    Relationship to This Procedure
    96413Initial chemotherapy administration, intravenous infusion technique; up to 1 hourCodes the primary initial chemotherapy infusion. 96413 is reported for the first agent in a multi-agent session before the add-on 96417 is reported for a different subsequent agent
    96415Chemotherapy administration, intravenous infusion technique; each additional hour (same drug)Used when the same chemotherapy agent requires additional hours of infusion beyond the time covered by 96413; not used for a different subsequent agent — 96417 is used when a different drug is given sequentially